IMUGENE LIMITED — Capital/Financing Update 2026

Feb 24, 2026

==> picture [177 x 31] intentionally omitted <==

ASX Announcement

Imugene receives $2.7m R&D tax refund

Sydney, Australia, 25 February 2026: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce it has received its research and development (R&D) tax refund for the 2025 financial year, totalling A$2,738,618, including interest of A$10,911.

The refund is received as part of the Australian Government's R&D Tax Incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 48.5%.

The refund received by Imugene will enable the further clinical development of its immuno-oncology pipeline. This funding comes at a pivotal time for the company following its recent FDA meeting and positive clinical results.

==> picture [527 x 31] intentionally omitted <==

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer info@imugene.com

Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

communications@imugene.com

Follow us on Twitter @TeamImugene Connect with us on LinkedIn @Imugene Limited View us on YouTube @Imugene Limited

==> picture [527 x 78] intentionally omitted <==

info@imugene.com

IMUGENE LIMITED ACN 009 179 551

WWW.IMUGENE.COM

==> picture [42 x 42] intentionally omitted <==

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (onCARlytics) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited

IMUGENE LIMITED ACN 009 179 551

2